AZ BioVentureHub
| Reference number | |
| Coordinator | AstraZeneca BioVentureHub AB |
| Funding from Vinnova | SEK 23 333 063 |
| Project duration | December 2014 - December 2019 |
| Status | Completed |
Important results from the project
Since the project was started, 38 companies have chosen to locate their business to BioVentureHub. In addition to Swedish companies, we have attracted companies from the UK, the Netherlands, Switzerland and the US. Overall, the companies have performed no less than 78 clinical studies and the majority of the companies have had significant growth during the period. We have entered into strategic collaborations with IBM and Mölnlycke Healthcare in order to further strengthen the innovation environment and the business has doubled the office space since the project started.
Expected long term effects
** Denna text är maskinöversatt ** BioVentureHub has contributed to strengthening Swedish life science in a number of ways. In addition to providing support to the companies, we have made a positive contribution to externally strengthening the image of Sweden as a unique innovation nation. Furthermore, we have helped to facilitate interactions and collaborations between industry and small companies and, on the whole, introduced a whole new innovation model which has attracted a great deal of attention, both nationally and internationally.
Approach and implementation
See attached final report